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Introduction: Four phase III randomized trials adding epidermal
growth factor receptor (EGFR)-tyrosine kinase inhibitors to standard
chemotherapeutics in patients with advanced non-small cell lung
cancer (NSCLC) have failed to show benefits. The mechanism of
these failures was examined.
Methods: Fifteen previously untreated NSCLC cell lines were
simultaneously treated with gefitinib plus cisplatin. Three exhibited
sensitizing-EGFR mutations. Three selected lines were further tested
with paclitaxel/cisplatin, paclitaxel/gefitinib, and paclitaxel/cispla-
tin/gefitinib combinations. The tetrazolium colorimetric assay with
application of the classic isobole method was used, and dose-versus-
log-response curves (DRCs) were analyzed to evaluate possible
resistance mechanisms.
Results: Of the 15 cell lines tested, combined gefitinib/cisplatin was
significantly antagonistic in 10 wild-type and three sensitizing-
EGFR mutant cell lines (group mean combination index  1.184,
95% confidence interval  1.12–1.24, p  0.001). The mean
combination index values of paclitaxel/cisplatin/gefitinib were
higher than or comparable with those of paclitaxel/cisplatin and
paclitaxel/gefitinib. DRC analysis consistently showed nonsaturable
passive resistance, suggesting that gefitinib at 0.001 to 0.3 M can
interfere with cisplatin cell entry (at concentrations 1–3 M) in a
dose-dependent manner and lead to antagonism. This antagonism
may or may not be schedule dependent in different cell lines.
Conclusions: In most EGFR wild-type or sensitizing-mutant NSCLC
cells, the concomitant gefitinib/cisplatin combination showed antag-
onism, likely because gefitinib interfered with cisplatin entry into the
cell. The findings that three-drug combination was not better than
the two-drug combinations are in accordance with the results of the
randomized trials. The EGFR-tyrosine kinase inhibitor/platinum
antagonism is a possible reason for the failure of those randomized
trials.
Key Words: Gefitinib, Cisplatin, Antagonism, Non-small cell lung
cancer.
(J Thorac Oncol. 2011;6: 559–568)
Platinum-based chemotherapy is the standard first-linetreatment for advanced non-small cell lung cancer
(NSCLC). Although it improves survival, treatment outcome
has reached a plateau.1 Among investigational strategies,
combination chemotherapy with targeted therapy is believed
to be promising.
In NSCLC, epidermal growth factor receptor-tyrosine
kinase inhibitors (EGFR-TKIs) are most effective in female
nonsmoking East Asians with adenocarcinomas2–4 and in
tumors with sensitizing-EGFR mutations.5–8 Unexpectedly,
combining EGFR-TKIs (gefitinib or erlotinib) with chemo-
therapy was no better than chemotherapy alone.9–12 Hypoth-
eses for this failure included the use of populations that were
not selected for sensitizing-EGFR mutations and use of in-
appropriate drug administration sequences leading to cell-
cycle-specific antagonism.13–17 A pharmacodynamic separa-
tion strategy was subsequently developed, with the hope of
overcoming cell-cycle-specific antagonism,13 but the effec-
tiveness of this strategy requires clinical confirmation, and
mechanisms of failure remain uncertain.
Several lines of evidence from clinical trials9–12,18,19
support a potentially negative interaction between EGFR-
TKIs and chemotherapy. Analysis of survival curves from
four randomized trials demonstrated a consistent finding: a
disturbing trend toward inferiority during the concurrent
EGFR-TKI-chemotherapy phase. In the TRIBUTE study,20
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EGFR mutations seemed to be predictive of a better response
in patients receiving frontline chemotherapy with versus
without erlotinib (53% versus 21%). Nevertheless, a better
response (70%) is expected in this group when they receive
frontline EGFR-TKI alone.21,22 Use of a platinum com-
pound was a common factor in all four trials. Thus, it is
worth examining EGFR-TKI-platinum interactions at the
cellular level, even though limited preclinical data showed
additive/supraadditive effects of EGFR-TKI in combina-
tion with various chemotherapeutics, including plati-
num.23–27 Of special interest is the question of whether tumor
cells with sensitizing-EGFR mutations would benefit more from
the combination.
In this study, we tested gefitinib combined with cispla-
tin in EGFR wild-type and mutant NSCLC cell lines, giving
them near-simultaneously, similar to the design of the ran-
domized trials. We found that combined gefitinib/cisplatin
therapy led to antagonism. Three-drug combinations (pacli-
taxel/cisplatin/gefitinib) were no better than two-drug com-
binations (paclitaxel/cisplatin or paclitaxel/gefitinib). The
data suggest that gefitinib interferes with cisplatin cell entry
and causes antagonism.
MATERIALS AND METHODS
Cell Lines and Culture
All 15 cell lines tested were established from previ-
ously untreated patients (Table 1).30 Four cell lines, H3255,
HCC827, PC-9, and H820, demonstrated EGFR gene muta-
tions. H820 also showed c-Met amplification.28,31 Five cell
lines, H23, H358, H460, H647, and H1155, were K-ras
mutants, and one cell line, H1299, was an N-rasmutant.29 All
cell lines were maintained and tested in RPMI 1640, supple-
mented with 5% heat-inactivated fetal bovine serum (R5), for
at least 3 months before being tested. All these cell lines were
genotyped by short tandem repeat profiling (AmpFlSTR Pro-
filer Plus ID Kit and AmpFlSTR Cofiler Kit, ABI PRISM 310
Genetic Analyzer, Applied Biosystems, Inc., Foster, USA) at
a national (Taiwan) validated laboratory of Clinical Center of
Allergy, Immunology, and Rheumatology, Buddhist Dalin
Tzu Chi General Hospital. The last date of authentication was
performed on November 24, 2009. Cell lines with EGFR
mutations were further confirmed by sequencing of exons 18
to 21 of EGFR gene and compatible drug sensitivities.
TABLE 1. Cell Line Characteristics and Results of In Vitro Drug Testing
Cell
Line Cell Typea EGFR Mutation28 Ras Mutation 29
Gefitinib,b IC50, M
(95% CI)
Cisplatin,b IC50, M
(95% CI)
mCIGCc
(95% CI)
Combination
Resultd
1 H23 A — K-ras 12 10.676 (10.298–11.053) 4.721 (4.556–4.887) 1.146 (1.051–1.240) Ant (12)
2 H125 AS — — 15.822 (15.667–15.977) 1.653 (1.102–2.204) 1.495 (1.049–1.942) Ant (12)
3 H226 S — — 8.990 (7.651–10.329) 1.303 (1.005–1.602) 1.243 (1.028–1.458) Ant (10)
4 H322 BAC — — 0.269 (0.160–0.377) 2.920 (2.144–3.696) 1.007 (0.905–1.110) Add (7)
5 H358 BAC — K-ras 12 6.086 (5.974–6.199) 4.203 (3.582–4.825) 1.010 (0.945–1.074) Add (11)
6 H460 LC — K-ras 61 10.089 (9.565–10.614) 0.879 (0.739–1.020) 1.147 (1.054–1.239) Ant (7)
7 H522 A — — 12.679 (12.094–13.264) 5.484 (0.606–10.362) 1.164 (1.018–1.310) Ant (8)
8 H647 AS — K-ras 13 12.474 (12.054–12.895) 5.792 (4.353–7.230) 1.258 (1.085–1.430) Ant (9)
9 H820 A del 746–749, T790M — 4.717 (4.694–4.738) 1.480 (1.053–1.907) 1.170 (1.025–1.314) Ant (9)
c-Met amplification
10 H838 AS — — 12.372 (12.104–12.640) 2.257 (1.783–2.731) 1.352 (1.020–1.685) Ant (11)
11 H1155 LC — K-ras 61 7.043 (6.925–7.160) 2.041 (1.857–2.225) 1.223 (1.017–1.429) Ant (9)
12 H1299 LC — N-ras 61 6.162 (6.003–6.320) 1.628 (1.101–2.155) 1.130 (1.019–1.242) Ant (9)
13 H3255 A L858R — 0.0042 (0.004–0.004) 7.388 (6.717–8.059) 1.055 (1.019–1.091) Ant (8)
14 HCC827 A del 746–750 — 0.0025 (0.002–0.003) 3.132 (0.461–5.802) 1.148 (1.030–1.270) Ant (9)
15 PC-9 A del 746–750 — 0.0235 (0.024–0.024) 0.568 (0.441–0.694) 1.219 (1.054–1.384) Ant (8)
Group results
Antagonism/additivity/synergism 13/2/0
Mean combination index (mCI), 95% CI 1.184, 1.12–1.24
pe 0.001
Resulte Antagonism
a A, adenocarcinoma; AS, adenosquamous cell carcinoma; S, squamous cell carcinoma; BAC, bronchioloalveolar cell carcinoma; LC, large cell carcinoma.
b The IC50 values were defined as the concentrations of drug that produced 50% reduction in control absorbance. For single agents tested, the results reported as IC50 were the
means and 95% confidence interval (CI) of three independently performed assays.
c The combination index of gefitinib plus cisplatin (GC) at the 50% effect level in a particular cell line was defined as the sum of the relative doses of each drug, which yields
an isoeffect (50% in this study) cell kill when added together and was used to represent the combination effects of test drugs. The mean values of the survival fractions of the three
independently performed experiments were used to generate the set of CI values (data points) and expressed as mean value (mCIGC).
d Ant, antagonism; Add, additivity. mCI values  1.05 or 0.95 are interpreted as being suggestive of antagonism and synergism, respectively. Sign tests were performed on
each set of CI values to formally evaluate whether antagonism (Ant) or synergism was evident for a particular cell line, otherwise was additivity (Add). Numbers in brackets, number
of data points.
e Wilcoxon signed rank test was applied to analyze the group data and concluded the group result.
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Drugs
Two chemotherapeutic agents, cisplatin (Sigma-Al-
drich, St. Louis, MO) and paclitaxel (Taxol; Bristol-Myers
Squibb, Princeton, NJ), and one EGFR-TKI, gefitinib (Iressa;
AstraZeneca Pharmaceuticals, Wilmington, DE), were tested.
The drugs were dissolved in dimethyl sulfoxide (for gefitinib
and paclitaxel) or phosphate-buffered saline (for cisplatin) to
100 mM. All agents were subsequently diluted with R5
before addition to cells.
Study Design and Drug Combinations
In vitro drug testing was performed using tetrazolium
dye [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazo-
lium bromide] colorimetric assays.32–34 Classic isobole meth-
ods were used to determine in vitro effects of drug combina-
tions.35 Results were expressed as the combination index
(CI).36 This model can qualitatively and quantitatively ana-
lyze the results of different drug combinations through the
entire range of dose-response curves of two32 or three33 tested
drugs, and different administration schedules.34 Importantly,
the results from this preclinical model have typically been
found to reflect clinical findings.32–34
The methodology is described in detail in Supple-
mentary appendix (Supplemental Digital Content 1,
http://links.lww.com/JTO/A44), and the study design is
described in Supplementary Figure 1 (Supplemental Dig-
ital Content 2, http://links.lww.com/JTO/A45). The cyto-
toxic effects of single-agent cisplatin (C) and gefitinib (G)
and the two-drug combination of gefitinib/cisplatin (GC)
were tested in all cell lines. The cytotoxic effects of the
single-agent paclitaxel, the two-drug combinations of ge-
fitinib/paclitaxel (GP) and paclitaxel/cisplatin (PC), and
the three-drug combination of paclitaxel/cisplatin/gefitinib
(PCG) were tested in the wild-type EGFR cell line H23,
and the cell lines harboring sensitizing-EGFR mutations,
H3255, and HCC827.
All drugs were tested over a 3-log range (seven con-
centrations, in 1/2-log increments) to cover the entire dose-
effect curve whenever possible, except for gefitinib in the
three-drug combination, which was tested at two fixed con-
centrations for each cell line: 1 M and 3 M for H23 cells,
and 0.0003 M and 0.001 M for H3255 and HCC827 cells.
These concentrations of gefitinib inhibited not more than 25%
of the cell activity.
Identification of Combination Effects
Cell survival was determined using [3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide] colorimet-
ric assays.32–34 The IC50 values were defined as concentra-
tions of drug producing a 50% reduction in control
absorbance. Mean values of the survival fractions of the three
independently performed experiments, each in quadruplicate
wells at the same time, were used to generate the set (data
points) of CI values (CI  [dose of drug A/IC50 of drug A]
 [dose of drug B/IC50 of drug B] for the two-drug combi-
nations, and CI  [dose of paclitaxel/IC50 of paclitaxel] 
[dose of cisplatin/IC50 of cisplatin]  [dose of gefitinib/IC50
of gefitinib] for the three-drug combination) and construct the
isobole for a particular cell line and drug combination.35
These mean survival fractions were also used to construct the
log-dose-versus-response curves and the dose-versus-log-re-
sponse curves (DRCs).
The mean CI (mCI) value for this set was reported as
the summary measure for each cell line. mCI values more
than 1.05 or less than 0.95 were interpreted as being sugges-
tive of antagonism and synergism, respectively.
Combined Gefitinib/Cisplatin with Different
Administration Schedule
Three administration schedules were tested in one wild-
type EGFR cell line, H125, and one EGFR-mutant cell line,
HCC827. The schedules were 24-hour sequential gefitinib-cis-
platin (G24 hoursC), near-simultaneous administration of ge-
fitinib-cisplatin (GC, gefitinib preceding cisplatin by 20 min-
utes), and 24-hour sequential cisplatin-gefitinib (C24 hoursG). For
each cell line, four plates for each schedule (a total of 12 plates)
were prepared. The study design of the experiments was the
same as that of the two-drug combination described earlier in the
text, except that the plates were incubated for 96 hours starting
from the addition of the first drug (gefitinib or cisplatin). Three
experiments were performed independently, and each experi-
ment was performed in quadruplicate wells.
Data Analysis
Sign tests were performed on each set of CI values to
formally evaluate whether antagonism or synergism was
evident for a particular cell line and drug combination at the
50% effect level. Additionally, Wilcoxon signed rank tests
were computed to evaluate whether significant differences in
the cell line means occurred, when compared with a null
hypothesized mCI of 1, and to analyze differences in drug
interactions in the tested regimens. Spearman’s rank correla-
tion was used to analyze correlations between the IC50 values
of the drugs and the mCIGC values of the cell lines. The
Mann-Whitney U rank sum test was used to test for differ-
ences between the mCI values of different drug-administra-
tion schedules and the mCI values of drug combinations of
the 6 ras mutant cell lines and the other 6 ras wild-type cell
lines. All tests were two sided, and p values less than 0.05
were deemed statistically significant.
DRC Analysis
Stewart et al.37,38 hypothesized that the DRC may offer
insight into the nature of drug-cell interactions and provide
information on how cancer cells become resistant after treat-
ment. DRCs show an initial shoulder for active resistance
(due to excess of a resistance factor such as a repair process
or efflux pump), a terminal plateau for saturable passive
resistance (due to deficiency or saturation of a factor required
for cell killing), and a change in the slope of the curve for
nonsaturable passive resistance (due to change or alteration of
a target, transport system, etc.), and combinations of these
mechanisms may exist in a given tumor or cell line.37
In this study, we plotted DRCs of the gefitinib-cisplatin
combination, examined the DRC shape and the effect of one
drug on the shape of the curve of another drug, and tried to
determine the nature of the drug interaction in every cell line
tested.
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RESULTS
Cell Lines, EGFR and Ras Gene Mutations, and
Drug Sensitivities
Cell-line characteristics and the results of in vitro test-
ing are listed in Table 1. Of the four cell lines harboring
mutant EGFR genes, three cell lines, H3255, HCC827, and
PC-9, exhibited sensitizing mutations and were supersensi-
tive to gefitinib; their IC50s to gefitinib were 0.0042, 0.0025,
and 0.0235 M, respectively, much lower than that of the
wild type. H820 had an sensitizing exon 19 deletion, the
resistant T790M mutation, and the resistant c-Met amplifica-
tion. It showed similar gefitinib insensitivity to the wild-type
EGFR lines and was deemed not to have an sensitizing-EGFR
mutation. All six ras mutants exhibited wild-type EGFR
genes and were gefitinib-insensitive.
Antagonism in the Gefitinib/Cisplatin
Combination and Its Correlation with Gefitinib
Sensitivity
When gefitinib was administered with cisplatin, 13 cell
lines showed antagonistic interactions, two were additive (Table
1, Figure 1). The mCI of the whole panel of 15 cell lines was
1.184 (95% confidence interval: 1.12–1.24), demonstrating an-
tagonism (p  0.001). All three lines with sensitizing-EGFR
mutations showed antagonism. The status of the ras gene in
these 15 cell lines showed no significant correlation to their
cisplatin sensitivity or mCI values (p values  0.05).
We found that the mCI value was closely correlated
with gefitinib sensitivity (R, 0.561, p  0.03; Supplemen-
tary Figure 2A, Supplemental Digital Content 3, http://
links.lww.com/JTO/A46) but not with cisplatin sensitivity
(R  0.268, p  0.334; Supplementary Figure 2B). The
higher degree of antagonism observed in cells with higher
gefitinib resistance suggests that gefitinib interferes with
cisplatin efficacy, rather than vice versa.
Three-Drug Combination is Not Better than
Two-Drug Combination
To test three-drug combinations, the EGFR wild-type
cell line H23 and two sensitizing-EGFR mutants, H3255
and HCC827, were chosen. As shown in Figure 2, Sup-
plementary Figure 3 (Supplemental Digital Content 4,
http://links.lww.com/JTO/A47) and Supplementary Table 1
(Supplemental Digital Content 1, http://links.lww.com/JTO/
A44), the gefitinib/cisplatin combination resulted in antago-
nism in all three cell lines. In H23, H3255, and HCC827,
combined paclitaxel/cisplatin showed additivity, antagonism,
and synergism, respectively, and combined gefitinib/pacli-
taxel showed additivity, additivity, and antagonism, respec-
tively. In H23, the mCI values of paclitaxel/cisplatin/gefitinib
treatment with both low- and high gefitinib concentrations
were markedly higher than those of gefitinib/paclitaxel and
paclitaxel/cisplatin, indicating that the three-drug combina-
tion gave statistically significantly inferior effects. H3255
showed a similar mCI for the three-drug and paclitaxel/
cisplatin combinations and a better mCI for gefitinib/pacli-
taxel (CIGP versus CIPCGL, p  0.05). In HCC827, the
three-drug combination with high-dose gefitinib was worse
than paclitaxel/cisplatin, as demonstrated by the higher mCI
values of the former, whereas three-drug combination with
low-dose gefitinib did no demonstrate antagonism. Hence, the
three-drug combination was not better than two-drug combi-
nations, regardless of the cell’s EGFR mutation status.
DRC Analysis
Because mCIGC values were significantly correlated
with IC50 values of gefitinib, we examined the DRCs of
cisplatin in the tested lines after addition of gefitinib to
explore the underlying mechanism of the antagonism (Fig-
ures 3A, B).
In this study, small shoulders were present on the initial
low-dose parts of the DRCs for the H23, H1155, and H3255
cell lines, suggesting low-level active resistance, but no
shoulders were seen in the others. For all cell lines except
H23 and H358, there was an initial steeper portion of the
curve followed by a shallower portion (Figure 3, arrow
heads) that became evident at cisplatin concentrations higher
than 1 to 3 M for most cell lines but at cisplatin doses less
than 1 M for H820 and H838 (Figure 3B). The change in
slope was greater for eight cell lines (Figure 3A) than for
other seven cell lines (Figure 3B).
The basic shapes of the cisplatin DRCs did not change
with the addition of gefitinib. Nevertheless, the slopes of the
DRCs consistently decreased with increasing gefitinib con-
centration, shifting the terminal portion of the DRC rightward
and upward (Figures 3A, B). No consistent changes were
observed in other DRC components. In most EGFR wild-type
cell lines (7/12; H460, H1299, H1155, H226, H125, H838,
and H23), a gefitinib concentration of 0.3 M elicited a slope
change in the cisplatin DRC, but a gefitinib concentration as
low as 0.001 M was sufficient to change the slope in the
FIGURE 1. Mean combination index (mCI) distribution of
the 15 cell lines. The group result is expressed as the mean
value (error bars: 95% confidence interval). The shaded area
represents the null interval of 0.95 to 1.05 for additivity. The
p value was analyzed by Wilcoxon signed rank test. The data
are representative of three independent experiments per-
formed in quadruplicate.
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sensitizing-EGFR mutants PC-9 and HCC827. The gefitinib
effect was clearly dose dependent.
Moreover, in the 12 of the 15 cell lines with mCI more
than 1.10, a gefitinib-induced slope decrease of the cisplatin
DRCs occurred when the cisplatin concentration was greater
than 1 to 3 M (Figure 3, arrows). That is, gefitinib had no
effect on the slope of the DRC when the cisplatin concentra-
tion was below 1 to 3 M.
Schedule-Dependent Gefitinib/Cisplatin
Interaction in H125 but Not in HCC827
Three different gefitinib/cisplatin administration sched-
ules, G24 hoursC, GC, and C24 hoursG, were tested in the EGFR
wild-type H125 and the sensitizing-EGFR mutant HCC827
lines. In H125, as reported previously, simultaneous admin-
istration of GC was antagonistic (mCI  1.39). The G24
hoursC schedule showed a numerically higher mCI (1.56) but
a similar degree of antagonism (p  0.429). In contrast, the
C24 hoursG schedule was additive, with the mCI (1.01) signif-
icantly lower than those of the G24 hoursC and GC schedules
(p values  0.002, Figure 4A, a).
DRC analysis of the GC schedule (Figure 4A, c)
showed enhanced nonsaturable passive resistance in a
gefitinib dose-dependent fashion. At the highest gefitinib
dose, the G24 hoursC schedule showed a reduced slope in the
FIGURE 2. Results of drug combinations in three selected cell lines. Panel A, The epidermal growth factor receptor (EGFR)
wild-type H23 cell ine. Left: (a) Log-dose-versus-response curves of the individual drugs, with seven concentrations in each (in
1/2-log increments for a 3-log range) to cover the entire curve whenever possible. GL and GH: high- and low-dose gefitinib
selected for testing in the three-drug combination (see text). Mean IC50 values and 95% confidence intervals (CIs, error bars)
calculated from the results of three independent assays performed in quadruplicate are shown. (b–f): Isobolograms of ge-
fitinib/cisplatin (GC), PC (paclitaxel/cisplatin), GP (gefitinib/paclitaxel), and PC plus low-dose (PCGL) or high-dose gefitinib
(PCGH). Data points (see text), generated from mean survival fractions of three independent experiments performed in qua-
druplicate, above the dashed additive diagonal line (Add) in the isobole suggest antagonism (Ant) and those below the diago-
nal suggest synergism (Syn). Sign tests were applied to each set of data points to formally evaluate whether synergism or an-
tagonism was evident for a particular cell line and drug combination. Right: Comparisons between mean combination index
(mCI) values of different combinations in the H23 cell lines. The differences were analyzed using Wilcoxon signed rank test.
NS, not statistically significant. Error bars correspond to 95% CIs. Numbers in the figure represent the CI values of the com-
bined regimens. Shaded area, additivity based on the null interval of 0.95 to 1.05. Comparisons between mCI values of differ-
ent combinations in the EGFR mutant cell lines H3255 (Panel B) and HCC827 (Panel C).
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FIGURE 3. Effects of gefitinib on the dose-versus-log-response curves of cisplatin in cell lines in which increment of cisplatin
cytotoxicity per se (with no gefitinib, close square), Panel A, decreased due to some saturable-passive resistance mechanism
or, Panel B, was proportionally, with dose increment at higher concentrations (1–3 M). The data are mean values and 95%
confidence intervals (error bars) of three independent experiments performed in quadruplicate. Arrow head: the point where
cisplatin activity per se was decreased and relied on less efficient mechanism(s) when the cisplatin concentration increased.
Arrow: the point where the slope began to show gefitinib-elicited change after adding different concentrations of gefitinib.
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terminal portion of the curve compared with cisplatin
alone, in keeping with nonsaturable passive resistance, but
the G24 hoursC schedule also showed a gefitinib-dose-
dependent progressive extension of a shoulder on the
curves when the cisplatin level exceeded 3 M (Figure
4A, b), suggesting the possible development of an addi-
tional active resistance mechanism. In contrast, the DRCs
of the C24 hoursG schedule (Figure 4A, d) showed very little
change after gefitinib exposure, indicating an additive
interaction.
In HCC827, schedule changes had little effect on the
antagonistic gefitinib/cisplatin interaction. The mCI values of
the G24 hoursC, GC, and C24 hoursG were similar (p values
0.4; Figure 4B, a). The DRCs of the three schedules (Figure
4B, b–d) demonstrated a saturable passive pattern without
notable shape changes after gefitinib addition.
DISCUSSION
In this study, the simultaneous administration of ge-
fitinib and cisplatin in a panel of previously untreated NSCLC
cell lines caused overall antagonism (group mCI  1.184,
p  0.001; 13/15 cell lines showed antagonism), which
correlated directly with gefitinib sensitivity. All three lines
with sensitizing-EGFR mutations showed antagonism. Sepa-
rate experiments testing a three-drug combination with ge-
fitinib plus doublet (paclitaxel/cisplatin) chemotherapy
showed that the three-drug combination was not better than
the two-drug regimens, regardless of the EGFR mutation
status of the cells. These findings are consistent with the
results of randomized trials,9–12 suggesting that EGFR-TKI/
platinum antagonism is a possible reason for the failure of
those trials.
FIGURE 4. Schedule-dependent effect of the gefitinib/cisplatin combination in Panel A, H125 and Panel B, HCC827. (a) com-
parisons of the mCI values of G24 hoursC, GC, and C24 hoursG (see text) by the Mann-Whitney U rank sum analyses. The
shaded horizontal band indicates the area of additivity, based on the null interval of 0.95–1.05. (b–d): The effects of adding
gefitinib on the cisplatin dose-versus-log-response curves in the different schedules. The data are mean values and 95% confi-
dence intervals (error bars) of three independent experiments performed in quadruplicate. Numbers in brackets indicate num-
bers of data points.
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The negative interaction between gefitinib and cisplatin
could be related to various cisplatin resistance mecha-
nisms.37–40 First, gefitinib may act to decrease cisplatin up-
take and/or increase efflux. Second, gefitinib may change the
susceptibility to DNA damage from cisplatin through increas-
ing DNA repair or increasing survival signals. Finally, anti-
apoptosis may be induced, changing the efficacy of cisplatin.
Among these mechanisms, increase of drug efflux, DNA repair,
and/or antiapoptotic factors indicates active resistance; de-
creased influx due to the altered intracellular pH or membrane
fluidity is nonsaturable passive resistance; and eventual satura-
tion of a transporter protein, a target, or an essential cofactor or
activating enzyme is a saturable passive mechanism.37
In this study, the DRCs of cisplatin alone showed a
steep portion at the initial low dose parts (or immediately
after the initial small shoulder). The curves showed a de-
crease in slope at a cisplatin concentration of 1 to 3 M for all
cell lines assessed except H23 and H358. These findings suggest
that there is a process that fosters cisplatin activity that is
saturated at higher drug doses, with cisplatin activity at higher
doses relying on less efficient mechanisms. The change in slope
beyond this concentration was greater for eight cell lines (Figure
3A) than for the other seven (Figure 3B).
Adding gefitinib decreased the slopes of the terminal
part of the cisplatin DRCs for almost all cell lines but did not
consistently change other components of the curves, such as
the initial shoulder, the slope of the initial portion of the
curve, or the cisplatin dose at which the slope changed.
Moreover, the antagonism showed a gefitinib-susceptibility-
related difference between cells with and without activating-
EGFR mutations (0.001 versus 0.3 M). Taken together, we
hypothesized that a low-capacity but high-efficiency process
results in rapid uptake of low-cisplatin doses and that this
process is not affected by gefitinib. Once this process is
saturated, a gefitinib-sensitive high-capacity but low-effi-
ciency process is responsible for further cisplatin uptake.
Cisplatin may enter cells by passive diffusion, by the copper
transporter CTR1 or by Na, K-ATPase.40 At higher cis-
platin doses, the gefitinib could either be altering passive
diffusion by damaging cell membranes (with greatest sensi-
tivity in the EGFR-mutant lines) or it could be noncompeti-
tively antagonizing a high-capacity/low-efficiency uptake
system that is responsible for further cisplatin uptake once the
high-efficiency system becomes saturated. Further studies are
planned to test the hypothesis that the observed gefitinib/
cisplatin antagonism is due to reduced cisplatin uptake by
gefitinib.
There have been conflicting findings on the interaction
between EGFR and platinum cytotoxicity.41–46 Friedmann et
al.42 demonstrated that the nuclear localization of EGFR was
key for DNA repair through the formation of EGFR and
DNA-dependent protein kinase (DNA-PK) complex after
cytotoxic exposure; thus, EGFR blockade could result in
enhanced cisplatin sensitivity.44,45 Nevertheless, Dixit et al.46
showed that decreased EGFR expression, through antisense
EGFR transfection, led to cisplatin resistance, with decreased
DNA adducts. In this study, we found gefitinib/cisplatin
antagonism in a nonsaturable passive resistance pattern, sug-
gesting that the antagonism did not involve the DNA repair
machinery, an active resistance mechanism.
A schedule-dependent interaction between platinum
and EGFR-TKI has been reported.47 We also demonstrated
that the cytotoxic effect of combined gefitinib/cisplatin was
schedule dependent in EGFR wild-type H125 cells: C24
hoursG was additive but G24 hoursC and simultaneous GC were
antagonistic. The explanation for the additive C24 hoursG
result is likely because cisplatin has inflexed into and dam-
aged cells with no interference before gefitinib being added
24 hours later. Both G24 hoursC (at the highest gefitinib dose)
and GC had terminal curve portions with decreased slope
suggestive of increased nonsaturable passive resistance, but
the G24 hoursC also had a DRC shoulder that increased with
gefitinib dose but that only became evident at higher cisplatin
doses. Active resistance mechanisms that give DRC shoul-
ders would generally be expected to have their greatest
impact at lowest drug doses.38 It is unknown why we saw a
shoulder developing beyond the DRC inflection point, but
one example of a potential mechanism for this would be
gefitinib-induced up-regulation of expression of a competi-
tive inhibitor of the high-capacity/low-efficiency cisplatin
transport system. In contrast, no schedule-dependent resis-
tance was obvious in activating-mutant HCC827 cells. The
different schedule effects on cell lines with or without acti-
vating-EGFR mutation deserve further investigation.
The mean steady-state serum concentration of gefitinib
after a fixed daily dose is 0.4 M.48 It is even higher for
erlotinib.49 It is reasonable to assume that when a patient with
NSCLC receives the combination of cisplatin and daily
EGFR-TKI therapy, antagonism between the drugs can occur.
If our findings are confirmed, then the apparent gefitinib/
cisplatin antagonism could potentially be abrogated by
changing the drug administration schedule. We suggest either
treating patients sequentially to avoid possible antagonism, in
which case the interval between the administration of plati-
num and EGFR-TKI should allow the TKI concentration to
fall below 0.001 M (0.3 M for EGFR wild-type tumors),
or using frequent low-dose cisplatin administration to main-
tain high dose intensity but with peak drug concentrations
low enough that cisplatin uptake can be accomplished en-
tirely by the saturable low-capacity/high-efficiency trans-
porter. We have demonstrated that not all chemotherapeutic
agents have similar effects when combined with EGFR-TKI
simultaneously in NSCLC cells: antimicrotubulins are a bet-
ter choice for combination with EGFR-TKIs than are gem-
citabine50 or cisplatin. The results of interactions of EGFR-
TKI-chemotherapeutics are cell line, drug, and administration
schedule dependent.
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In conclusion, simultaneous gefitinib/cisplatin combi-
nation showed antagonism in NSCLC cells, regardless of
their EGFR mutation status. We suggest that this may be due
to reduced cisplatin influx by gefitinib. The findings that a
three-drug combination was not better than two-drug combi-
nations are consistent with results seen in clinical studies. The
antagonism is a possible reason for the failure of those
clinical studies and could be potentially abrogated by chang-
ing drug administration schedule.
ACKNOWLEDGMENTS
Supported, in part, by grants from the National Science
Council (NSC94–2314-B-075-100 and NCS97-2314-B-075-
042-MY3), the Center of Excellence for Cancer Research at
Taipei Veterans General Hospital (DOH99-TD-C-111-007),
and the Taipei Veteran General Hospital (V92C1-318,
V97C1-124, and V98C1-030).
The authors thank Dr. Shu-Chiung Chiang for assis-
tance in statistical computation; Dr. Mien-Chie Hung for
providing cell lines H3255 and HCC827; Dr. Chih-Hsin
Yang for providing P-9; and Ms. Yu-Wen Chang and Ms.
Chun-Min Kao for preparing the manuscript.
REFERENCES
1. Socinski MA. Cytotoxic chemotherapy in advanced non-small cell lung
cancer: a review of standard treatment paradigms. Clin Cancer Res
2004;10:4210s–4214s.
2. Giaccone G. The role of gefitinib in lung cancer treatment. Clin Cancer
Res 2004;10:4233s–4237s.
3. Kelly K, Huang C. Biological agents in non-small cell lung cancer: a
review of recent advances and clinical results with a focus on epidermal
growth factor receptor and vascular endothelial growth factor. J Thorac
Oncol 2008;3:664–673.
4. Chiu CH, Tsai CM, Chen YM, et al. Gefitinib is active in patients with
brain metastases from non-small cell lung cancer and response is related
to skin toxicity. Lung Cancer 2005;47:129–138.
5. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the
epidermal growth factor receptor underlying responsiveness of non-
small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129–2139.
6. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer:
correlation with clinical response to gefitinib therapy. Science 2004;304:
1497–1500.
7. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are
common in lung cancers from “never smokers” and are associated with
sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA
2004;101:13306–13311.
8. Chou TY, Chiu CH, Li LH, et al. Mutation in the tyrosine kinase domain
of epidermal growth factor receptor is a predictive and prognostic factor
for gefitinib treatment in patients with non-small cell lung cancer. Clin
Cancer Res 2005;11:3750–3757.
9. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination
with gemcitabine and cisplatin in advanced non-small-cell lung cancer:
a phase III trial–INTACT 1. J Clin Oncol 2004;22:777–784.
10. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with
paclitaxel and carboplatin in advanced non-small-cell lung cancer: a
phase III trial–INTACT 2. J Clin Oncol 2004;22:785–794.
11. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of
erlotinib hydrochloride (OSI-774) combined with carboplatin and pac-
litaxel chemotherapy in advanced non-small-cell lung cancer. J Clin
Oncol 2005;23:5892–5899.
12. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of
erlotinib in combination with cisplatin and gemcitabine in advanced
non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial.
J Clin Oncol 2007;25:1545–1552.
13. Davies AM, Ho C, Lara PN Jr, et al. Pharmacodynamic separation of
epidermal growth factor receptor tyrosine kinase inhibitors and chemo-
therapy in non-small-cell lung cancer. Clin Lung Cancer 2006;7:385–
388.
14. Gandara DR, Gumerlock PH. Epidermal growth factor receptor tyrosine
kinase inhibitors plus chemotherapy: case closed or is the jury still out?
J Clin Oncol 2005;23:5856–5858.
15. Normanno N. Gefitinib and cisplatin-based chemotherapy in non-small-
cell lung cancer: simply a bad combination? J Clin Oncol 2005;23:928–
930, author reply 930–931.
16. Baselga J. Combining the anti-EGFR agent gefitinib with chemotherapy
in non-small-cell lung cancer: how do we go from INTACT to impact?
J Clin Oncol 2004;22:759–761.
17. Milano G, Spano JP, Leyland-Jones B. EGFR-targeting drugs in com-
bination with cytotoxic agents: from bench to bedside, a contrasted
reality. Br J Cancer 2008;99:1–5.
18. Stinchcombe TE, Morris DE, Lee CB, et al. Induction chemotherapy
with carboplatin, irinotecan, and paclitaxel followed by high dose
three-dimension conformal thoracic radiotherapy (74 Gy) with concur-
rent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and
stage IIIB non-small cell lung cancer. J Thorac Oncol 2008;3:250–257.
19. Choong NW, Mauer AM, Haraf DJ, et al. Phase I trial of erlotinib-based
multimodality therapy for inoperable stage III non-small cell lung
cancer. J Thorac Oncol 2008;3:1003–1011.
20. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal
growth factor receptor and in KRAS are predictive and prognostic
indicators in patients with non-small-cell lung cancer treated with
chemotherapy alone and in combination with erlotinib. J Clin Oncol
2005;23:5900–5909.
21. Riely GJ, Politi KA, Miller VA, et al. Update on epidermal growth factor
receptor mutations in non-small cell lung cancer. Clin Cancer Res
2006;12:7232–7241.
22. Yang CH, Yu CJ, Shih JY, et al. Specific EGFR mutations predict
treatment outcome of stage IIIB/IV patients with chemotherapy-naive
non-small-cell lung cancer receiving first-line gefitinib monotherapy.
J Clin Oncol 2008;26:2745–2753.
23. Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentia-
tion of cytotoxic drugs activity in human cancer cells by ZD-1839
(Iressa), an epidermal growth factor receptor-selective tyrosine kinase
inhibitor. Clin Cancer Res 2000;6:2053–2063.
24. Raben D, Helfrich BA, Chan D, et al. ZD1839, a selective epidermal
growth factor receptor tyrosine kinase inhibitor, alone and in combina-
tion with radiation and chemotherapy as a new therapeutic strategy in
non-small cell lung cancer. Semin Oncol 2002;29:37–46.
25. Sirotnak FM, Zakowski MF, Miller VA, et al. Efficacy of cytotoxic
agents against human tumor xenografts is markedly enhanced by coad-
ministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
Clin Cancer Res 2000;6:4885–4892.
26. Higgins B, Kolinsky K, Smith M, et al. Antitumor activity of erlotinib
(OSI-774, Tarceva) alone or in combination in human non-small cell
lung cancer tumor xenograft models. Anticancer Drugs 2004;15:503–
512.
27. Gieseg MA, de Bock C, Ferguson LR, et al. Evidence for epidermal
growth factor receptor-enhanced chemosensitivity in combinations of
cisplatin and the new irreversible tyrosine kinase inhibitor CI-1033.
Anticancer Drugs 2001;12:683–690.
28. Engelman JA, Zejnullahu K, Gale CM, et al. PF00299804, an irrevers-
ible pan-ERBB inhibitor, is effective in lung cancer models with EGFR
and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007;
67:11924–11932.
29. Mitsudomi T, Viallet J, Mulshine JL, et al. Mutations of ras genes
distinguish a subset of non-small-cell lung cancer cell lines from small-
cell lung cancer cell lines. Oncogene 1991;6:1353–1362.
30. Gazdar AF, Kadoyama C, Venzon D, et al. Association between histo-
logical type and neuroendocrine differentiation on drug sensitivity of
lung cancer cell lines. J Natl Cancer Inst 1992;Monogr:191–196.
31. Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or
without T790M mutations in EGFR mutant lung tumors with acquired
resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007;104:
20932–20937.
32. Tsai CM, Chang KT, Chen JY, et al. Cytotoxic effects of gemcitabine-
containing regimens against human non-small cell lung cancer cell lines
Journal of Thoracic Oncology • Volume 6, Number 3, March 2011 Antagonism between Gefitinib and Cisplatin in NSCLC
Copyright © 2011 by the International Association for the Study of Lung Cancer 567
which express different levels of p185neu. Cancer Res 1996;56:794–
801.
33. Tsai CM, Hsiao SH, Frey CM, et al. Combination cytotoxic effects of
cis-diamminedichloroplatinum(II) and 5-fluorouracil with and without
leucovorin against human non-small cell lung cancer cell lines. Cancer
Res 1993;53:1079–1084.
34. Tsai CM, Gazdar AF, Perng RP, et al. Schedule-dependent in vitro
combination effects of methotrexate and 5-fluorouracil in human tumor
cell lines. Int J Cancer 1991;47:401–407.
35. Berenbaum MC. Synergy, additivism and antagonism in immunosup-
pression. A critical review. Clin Exp Immunol 1977;28:1–18.
36. Chou TC, Talalay P. Quantitative analysis of dose-effects relationships:
the combined effect of multiple drugs on enzyme inhibitors. Adv Enzyme
Regul 1985;22:27–55.
37. Stewart DJ, Raaphorst GP, Yau J, et al. Active vs. passive resistance,
dose-response relationships, high dose chemotherapy, and resistance
modulation: a hypothesis. Invest New Drugs 1996;14:115–130.
38. Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. Crit
Rev Oncol Hematol 2007;63:12–31.
39. Hall MD, Okabe M, Shen DW, et al. The role of cellular accumulation
in determining sensitivity to platinum-based chemotherapy. Annu Rev
Pharmacol Toxicol 2008;48:495–535.
40. Stewart DJ. Tumor and host factors that may limit efficacy of chemo-
therapy in non-small cell and small cell lung cancer. Crit Rev Hemat
Oncol 2010;75:173–234.
41. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat
Rev Cancer 2007;7:573–584.
42. Friedmann B, Caplin M, Hartley JA, et al. Modulation of DNA repair in
vitro after treatment with chemotherapeutic agents by the epidermal
growth factor receptor inhibitor gefitinib (ZD1839). Clin Cancer Res
2004;10:6476–6486.
43. Christen RD, Hom DK, Porter DC, et al. Epidermal growth factor
regulates the in vitro sensitivity of human ovarian carcinoma cells to
cisplatin. J Clin Invest 1990;86:1632–1640.
44. Friedmann BJ, Caplin M, Savic B, et al. Interaction of the epidermal
growth factor receptor and the DNA-dependent protein kinase pathway
following gefitinib treatment. Mol Cancer Ther 2006;5:209–218.
45. Dittmann K, Mayer C, Fehrenbacher B, et al. Radiation-induced
epidermal growth factor receptor nuclear import is linked to activa-
tion of DNA-dependent protein kinase. J Biol Chem 2005;280:
31182–31189.
46. Dixit M, Yang JL, Poirier MC, et al. Abrogation of cisplatin-induced
programmed cell death in human breast cancer cells by epidermal
growth factor antisense RNA. J Natl Cancer Inst 1997;89:365–373.
47. Xu JM, Azzariti A, Colucci G, et al. The effect of gefitinib (Iressa,
ZD1839) in combination with oxaliplatin is schedule-dependent in colon
cancer cell lines. Cancer Chemother Pharmacol 2003;52:442–448.
48. Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharmacokinetic,
and pharmacodynamic trial of ZD1839, a selective oral epidermal
growth factor receptor tyrosine kinase inhibitor, in patients with five
selected solid tumor types. J Clin Oncol 2002;20:4292–4302.
49. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study
of OSI-774, an epidermal growth factor receptor tyrosine kinase inhib-
itor, in patients with advanced solid malignancies. J Clin Oncol 2001;
19:3267–3279.
50. Tsai CM, Chang KT, Chiu CH, et al. The synergistic effects between
gefitinib and anti-microtubule agents in non-small-cell lung cancer cells
and selected patients. J Thoracic Oncol 2009;4:S555 (suppl 19; abstr
PD10.3.5).
Tsai et al. Journal of Thoracic Oncology • Volume 6, Number 3, March 2011
Copyright © 2011 by the International Association for the Study of Lung Cancer568
